Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Foslevodopa/foscarbidopa improves nocturia symptoms in patients with Parkinson’s disease

Ray Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, describes the findings of two Phase III trials looking at nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa. The trials focused on a subcutaneous delivery system of levodopa, which showed positive results in improving motor parameters. Additionally, the continuous delivery of levodopa was found to have a significant impact on reducing nocturia, both in the randomized placebo control phase and during the open-label extension. This improvement may be attributed to the drug’s effect on the dopamine D1 receptor, which influences bladder function. Nocturnal off periods, often associated with non-motor fluctuations and urinary dysfunction, were specifically targeted. The presented data suggests potential benefits of the subcutaneous pro-drug in managing these symptoms. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.